Targets › GPRC5D
15 programs from 13 companies in 66 trials: 29 Phase 1, 27 Phase 2, 9 Phase 3, 1 Phase 4; Oncology, Other, Immunology; next expected readout Nov 2026.
G protein-coupled receptor involved in hard keratin expression and likely plays a role in the development of hair and nails. (UniProt, Q9NZD1)
Open in Phaseline: the race on GPRC5D, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals | Linvoseltamab anti-B-cell maturation antigen x anti-CD3 bispecific antibody | BCMA, GPRC5D, CD3E, TNFRSF17 | Phase 4 | Relapsed/Refractory Multiple Myeloma (RRMM); Relapsed and/or Refractory Multiple Myeloma (RRMM); Relapsed Refractory Multiple Myeloma (RRMM); High Risk Smoldering Multiple Myeloma (HR-SMM) … | Aug 2027 |
| Johnson & Johnson (Janssen) | Talquetamab T cell surface glycoprotein CD3 binding agent; G-protein coupled receptor family C group 5 member D binding agent | CD3E, CD3G, CD3D, GPRC5D | Phase 3 | Multiple Myeloma; Hematological Malignancies; Relapsed/ Refractory Multiple Myeloma; Multiple Myeloma (MM) … | Apr 2027 |
| Johnson & Johnson (Janssen) | Ramantamig BCMAxGPRC5DxCD3 trispecific antibody | TNFRSF17, CD3E, BCMA, GPRC5D | Phase 3 | Multiple Myeloma | Dec 2027 |
| Institute of Hematology & Blood Diseases Hospital, China | GPRC5D/CD3 BiTEs Bispecific T-cell engager targeting GPRC5D and CD3 | GPRC5D, CD3E | Phase 2 | Multiple Myeloma, Newly Diagnosed; Multiple Myeloma, Plasma Cell Leukemia | Aug 2027 |
| Institute of Hematology & Blood Diseases Hospital, China | QLS4131 BCMA/GPRC5D/CD3 trispecific antibody | BCMA, GPRC5D, CD3 | Phase 2 | Primary Plasma Cell Leukemia | Dec 2029 |
| OriCell Therapeutics | OriCAR-017 GPRC5D-directed chimeric antigen receptor (CAR) modified T cells | GPRC5D | Phase 1 | Relapsed and/or Refractory Multiple Myeloma; Neoplasms, Plasma Cell | Nov 2026 |
| Beijing GoBroad Hospital | Dual-targeting BCMA-GPRC5D CAR-T cell Dual-target CAR-T cell therapy targeting BCMA and GPRC5D | BCMA, GPRC5D | Phase 1 | Relapsed or Refractory Multiple Myeloma (RRMM) | May 2027 |
| Peking University First Hospital | GPRC5D-targeted radiotracer GPRC5D-targeted PET radiotracer | GPRC5D | Phase 1 | Plasma Cell Disorders | May 2027 |
| Bayer | Actinium-225-macropa-pelgifatamab (BAY3546828) Alpha-emitting radiopharmaceutical targeting GPRC5D; actinium-225 chelated by macropa conj | GPRC5D | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Jun 2027 |
| Essen Biotech | BCMA/GPRC5D CAR-T cells Chimeric Antigen Receptor T cells targeting BCMA and/or GPRC5D | BCMA, GPRC5D | Phase 1 | Multiple Myeloma | Dec 2027 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical | TQB2029 for injection bispecific antibody targeting GPRC5D and CD3; recruits and activates CD3+ T cells to kill | GPRC5D, CD3 | Phase 1 | Multiple Myeloma | Mar 2028 |
| O&D BioTech Group | O&D-001 injection Chimeric antigen receptor T cell targeting BCMA and GPRC5D | BCMA, GPRC5D | Phase 1 | Relapsed or Refractory Multiple Myeloma | Mar 2028 |
| Bristol-Myers Squibb | Alnuctamab (BMS-986349, CC-93269, EM901) GPRC5D-targeting monoclonal antibody | GPRC5D | Phase 1 | Multiple Myeloma; Systemic Lupus Erythematosus | Aug 2028 |
| Chunrui Li | CAR-GPRC5D CAR-T cell therapy targeting GPRC5D | GPRC5D | Phase 1 | Relapsed/Refractory Multiple Myeloma | – |
| Nanjing IASO Biotechnology | CAR-GPRC5D (RD118) anti-GPRC5D CAR-T cell therapy | GPRC5D | Phase 1 | Relapsed/Refractory Multiple Myeloma | – |
Multiple Myeloma (32) Relapsed Refractory Multiple Myeloma (RRMM) (3) Relapsed/Refractory Multiple Myeloma (3) Multiple Myeloma, Newly Diagnosed (2) Hematological Malignancies (2) Multiple Myeloma (MM) (2) Relapsed/Refractory Multiple Myeloma (RRMM) (1) Relapsed and/or Refractory Multiple Myeloma (RRMM) (1) High Risk Smoldering Multiple Myeloma (HR-SMM) (1) Monoclonal Gammopathy of Undetermined Significance (MGUS) (1) Smoldering Multiple Myeloma (SMM) (1) Food Allergy (1)
mixed (5), other (4), small molecule (3), antibody (1), protein or peptide (1)
Johnson & Johnson (Janssen) (2) Institute of Hematology & Blood Diseases Hospital, China (2) Regeneron Pharmaceuticals (1) Bristol-Myers Squibb (1) Nanjing IASO Biotechnology (1) Beijing GoBroad Hospital (1) O&D BioTech Group (1) Essen Biotech (1) OriCell Therapeutics (1) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical (1) Bayer (1) Chunrui Li (1) Peking University First Hospital (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.